Sugi Predict

Sugi Predict / Compounds / SCHEMBL932887

SCHEMBL932887

SCHEMBL932887

N#Cc1ccc(OC(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ PKM P14618 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CCR6 P51684 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ CA2 P00918 2/20 0.44
▸ CA9 Q16790 2/20 0.44
▸ CA1 P00915 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MAOB P27338 1/20 0.42
▸ DRD1 P21728 1/20 0.42
▸ ALOX15 P16050 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ ADAM17 P78536 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6378888 0.94 DRD1 (0.52) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL14473444 0.87 GAA (0.43) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL28895840 0.83 GAA (0.44) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL16587855 0.82 SLC6A2 (0.45) GAASMN1; SMN2CYP2A6TDP2KCNH2
SCHEMBL4121767 0.82 MAPT (0.69) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL2797770 0.81 ACACB (0.51) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL11065049 0.80 DRD1 (0.56) ALDH1A1MEN1LMNAPKMKMT2A
SCHEMBL24665318 0.78 OPRM1 (0.43) ALDH1A1MEN1LMNAKMT2AGAA
SCHEMBL30731692 0.78 OPRM1 (0.43) ALDH1A1MEN1LMNAKMT2AGAA
SCHEMBL105821 0.77 ALDH1A3 (0.47) ALDH1A1KMT2ACA2CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102351787-B High-bioavailability roflumilast compound TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD 2014-08-13 — — CN claimed
CN-102351787-A High-bioavailability roflumilast compound TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD 2012-02-15 — — CN claimed
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2026-05-07 — — US disclosed
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 — — US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 — — US disclosed
US-12370194-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2025-07-29 — — US disclosed
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2024-09-19 — — US disclosed
US-11938134-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
CN-112279845-B Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof 中国医学科学院药物研究所 2023-07-28 — — CN disclosed
CN-115867541-A Aminopyrimidinone derivatives 豪夫迈·罗氏有限公司 2023-03-28 — — CN disclosed
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-03-16 — — US disclosed
US-6200993-B1 ASTHMA; ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA & CO. (CA) 2001-03-13 — — US disclosed
EP-1070708-A1 Triazole and imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-01-24 — — EP disclosed
EP-0812308-A4 METHOD FOR SYNTHESIS OF ARYL DIFLUOROMETHYL ETHERS AND THE LIKE SMITHKLINE BEECHAM CORP (US) 1999-03-31 — — EP disclosed
US-5731477-A Method for synthesis of aryl difluoromethyl ethers SMITHKLINE BEECHAM CORPORATION (US) 1998-03-24 — — US disclosed
EP-0812308-A1 METHOD FOR SYNTHESIS OF ARYL DIFLUOROMETHYL ETHERS AND THE LIKE SMITHKLINE BEECHAM CORPORATION (US) 1997-12-17 — — EP disclosed
WO-1996023754-A1 METHOD FOR SYNTHESIS OF ARYL DIFLUOROMETHYL ETHERS AND THE LIKE SMITHKLINE BEECHAM CORPORATION (US) 1996-08-08 — — WO disclosed
EP-0125248-A1 INSECTICIDAL SUBSTITUTED-BIPHENYLMETHYL OXIME ETHERS FMC Corporation (US) 1984-11-21 — — EP disclosed
WO-1984001772-A1 INSECTICIDAL SUBSTITUTED-BIPHENYLMETHYL OXIME ETHERS FMC CORP (US) 1984-05-10 — — WO disclosed
US-4434182-A Insecticidal substituted-biphenylmethyl oxime ethers FMC CORPORATION (US) 1984-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC1, HDAC2 ALDH1A1 244/4885MEN1 2833/4885LMNA 4039/4885
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 ALDH1A1 347/4885MEN1 658/4885LMNA 3750/4885
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC3, HDAC1 ALDH1A1 780/4885MEN1 4744/4885LMNA 3751/4885
US-11938134-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 ALDH1A1 244/4885MEN1 2833/4885LMNA 4039/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 ALDH1A1 1031/4885MEN1 2249/4885LMNA 2111/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 ALDH1A1 347/4885MEN1 658/4885LMNA 3750/4885
US-12370194-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 ALDH1A1 244/4885MEN1 2833/4885LMNA 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.